A Phase 3 interventional study of Enoxaparin and Apixaban in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 122 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.
Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 3rd registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Rushad Patell · Sites in United States
Ages 18+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
James Bayley · Sites in United States
Ages 18+
University Hospital, Geneva
Ages 18–120
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,221 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 445 across the 26 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing apixaban in Venous Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07713875James BayleyExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing apixaban in Venous Thrombosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare the efficacy of apixaban with that of enoxaparin (Lovenox®) in the prevention of these clots. The safety of apixaban will also be studied.
Key Inclusion Criteria
Key Exclusion Criteria
laboratory abnormalities at the enrollment visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
Drug: Apixaban · Drug: Enoxaparin-matching placebo
Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
Drug: Enoxaparin · Drug: Apixaban-matching placebo
40 mg, administered once daily by subcutaneous injection, for 12 days
Also known as: Lovenox®
2.5 mg, administered twice daily as tablets, for 12 days
Also known as: BMS-562247
Administered once daily by subcutaneous injection
Oral tablet administered twice daily
Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.
Time frame: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug
Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.
Time frame: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study
Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM
Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment.
Time frame: Days 1 to 12
Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs.
Time frame: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug
Summary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements)
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): \>2 decrease from preRx value or value \<=8; hematocrit (%): \<0.75\*preRx; platelets: \<100\*10\^9 cells/L; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx; leukocytes: \<0.75\*LLN or \>1.25\*ULN, or if preRx \<LLN, use \<0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; abs basophils: \>400/mm\^3; abs eosinophils: \> 0.750\*10\^3 cells/µL; abs lymphocytes: \<0.750\*10\*3 cells/ µL or \>7.50\*10\^3 c/ µL; abs monocytes \> 2000/mm\^3; abs neutrophils: \<1.0\*10\^3 cells/μL; ALP (U/L): \>2\*ULN; ALT, AST (U/L): \>3\*ULN; U/L; bilirubin, direct (mg/dL): \>1.5\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN.
Time frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
Summary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements)
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): \<0.8\*LLN or \>1.2\*ULN, or if preRx\<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; chloride, serum (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9\*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; bicarbonate (mEq/L): \<0.75\*LLN or \>1.25\*ULN, or if preRx \< LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \< LLN; potassium, serum (mEq/L): \<0.9\* LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9 \*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; sodium, serum (mEq/L): \<0.95\*LLN or \>1.05\*ULN, or if preRx \<LLN use \<0.95\*preRx or \>ULN if preRx\>ULN use \>1.05\*preRx or \<LLN; protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use 0.9\*preRx or \>ULN if preRx \>ULN use 1.1\*preRx or \<LLN; CK (U/L): \>5\*ULN; uric acid (mg/dL): \>1.5\*ULN, or if preRx \>ULN use \>2\*preRx; glucose, fasting serum (mg/dL): \<0.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<0.8\*preRx or \>ULN.
Time frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
Summary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis)
preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4.
Time frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up
| Milestone | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Started | 1528 | 1529 |
| Received treatment | 1501 | 1508 |
| Evaluable participants | 907 | 921 |
| Primary participants | 976 | 997 |
| Completed | 1392 | 1393 |
| Not completed | 136 | 136 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 40 | 44 |
| Withdrew: Withdrawal by subject | 68 | 57 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Poor compliance/noncompliance | 1 | 2 |
| Withdrew: No longer met study criteria | 18 | 22 |
| Withdrew: Other | 7 | 11 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.
| Percentage of events/patients evaluated | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period | 1.09 (0.62 to 1.88) | 2.17 (1.47 to 3.18) |
Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment.
| Percentage of events/patients evaluated | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Major bleeding (n=9, 14) | 0.60 (0.30 to 1.16) | 0.93 (0.54 to 1.57) |
| CRNM (n=44, 58) | 2.93 (2.19 to 3.93) | 3.85 (2.98 to 4.95) |
| Major bleeding or CRNM (n=53, 72) | 3.53 (2.71 to 4.60) | 4.77 (3.81 to 5.98) |
| Any bleeding | 6.93 (5.75 to 8.34) | 8.36 (7.06 to 9.87) |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.
| Percentage of events/patients evaluated | Apixaban, 2.5 mg BID | Enoxaparin, 40 mg QD |
|---|---|---|
| Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period | 15.06 (12.95 to 17.46) | 24.37 (21.81 to 27.14) |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs.
| Participants | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| SAE | 72 | 88 |
| Bleeding AE | 90 | 112 |
| Discontinuations due to AEs | 40 | 44 |
| Deaths | 2 | 0 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): \>2 decrease from preRx value or value \<=8; hematocrit (%): \<0.75\*preRx; platelets: \<100\*10\^9 cells/L; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx; leukocytes: \<0.75\*LLN or \>1.25\*ULN, or if preRx \<LLN, use \<0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; abs basophils: \>400/mm\^3; abs eosinophils: \> 0.750\*10\^3 cells/µL; abs lymphocytes: \<0.750\*10\*3 cells/ µL or \>7.50\*10\^3 c/ µL; abs monocytes \> 2000/mm\^3; abs neutrophils: \<1.0\*10\^3 cells/μL; ALP (U/L): \>2\*ULN; ALT, AST (U/L): \>3\*ULN; U/L; bilirubin, direct (mg/dL): \>1.5\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN.
| Participants | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Hemoglobin, low (n=1424, 1442) | 1127 | 1178 |
| Hematocrit, low n=(1369, 1396) | 668 | 723 |
| Platelet count, low (n=1413, 1425) | 7 | 5 |
| Erythrocytes, low (n=1368, 1396) | 690 | 735 |
| Leukocytes, low (n=1457, 1471) | 27 | 26 |
| Leukocytes, high (n=1457, 1471) | 193 | 213 |
| Basophils (absolute), high (n=1448, 1465) | 2 | 4 |
| Eosinophils (absolute), high (n=1448, 1465) | 43 | 60 |
| Lymphocytes (absolute), low (n=1448, 1465) | 203 | 215 |
| Lymphocytes (absolute), high (n=1448, 1465) | 1 | 0 |
| Monocytes (absolute), high (n=1448, 1465) | 5 | 2 |
| Neutrophils (absolute), low (n=1448, 1465) | 5 | 2 |
| Alkaline phosphatase (ALP), high (n=1465, 1476) | 15 | 31 |
| Alanine aminotransferase (ALT), high (n=1459,1472) | 32 | 26 |
| Aspartate aminotransferase (AST) , high (n=1459,14 | 34 | 26 |
| Bilirubin, direct (high) (n=1447,1457) | 87 | 76 |
| Bilirubin, total (high) (n=1461,1476) | 15 | 9 |
| Blood urea nitrogen (BUN) (high)(n=1447,1458) | 15 | 17 |
| Creatinine (high) (n=1447,1458) | 17 | 23 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): \<0.8\*LLN or \>1.2\*ULN, or if preRx\<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; chloride, serum (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9\*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; bicarbonate (mEq/L): \<0.75\*LLN or \>1.25\*ULN, or if preRx \< LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \< LLN; potassium, serum (mEq/L): \<0.9\* LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9 \*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; sodium, serum (mEq/L): \<0.95\*LLN or \>1.05\*ULN, or if preRx \<LLN use \<0.95\*preRx or \>ULN if preRx\>ULN use \>1.05\*preRx or \<LLN; protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use 0.9\*preRx or \>ULN if preRx \>ULN use 1.1\*preRx or \<LLN; CK (U/L): \>5\*ULN; uric acid (mg/dL): \>1.5\*ULN, or if preRx \>ULN use \>2\*preRx; glucose, fasting serum (mg/dL): \<0.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<0.8\*preRx or \>ULN.
| Participants | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Calcium, total (low) (n=1447, 1457) | 5 | 9 |
| Chloride, serum (low)(n=1442, 1454) | 1 | 0 |
| Bicarbonate (low) (n=1435, 1447) | 0 | 3 |
| Potassium, serum (low) (n=1438, 1453) | 38 | 41 |
| Potassium, serum (high)(n=1438, 1453) | 34 | 40 |
| Sodium, serum (low) (n=1442, 1454) | 5 | 10 |
| Sodium, serum (high) (n=1442, 1454) | 1 | 0 |
| Glucose, fasting serum (low) (n=715, 713) | 8 | 1 |
| Glucose, fasting serum (high) (n=715, 713) | 46 | 25 |
| Protein, total (low) (n=1447, 1457 | 223 | 243 |
| Creatine kinase (CK) (high) (n=1463, 1476) | 66 | 65 |
| Uric acid (high) (n=1446, 1458) | 1 | 2 |
preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4.
| Participants | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Blood, urine (high) (n=1421, 1430) | 169 | 113 |
| Glucose, urine (high) (n=1421, 1429) | 160 | 154 |
| Protein, urine (high) (n=1421, 1430) | 60 | 89 |
| Red blood cells, urine (high) (n=441, 385) | 133 | 116 |
| White blood cells, urine (high)(n=441, 386) | 101 | 102 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixiban, 2.5 mg BID Plus Placebo | — | 72/1,501 (4.8%) | 295/1,501 (19.7%) |
| Enoxaparin, 40 mg QD Plus Placebo | — | 88/1,508 (5.8%) | 342/1,508 (22.7%) |
| Event | Apixiban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Deep vein thrombosisVascular disorders | 11/1501 | 22/1508 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/1501 | 1/1508 |
| Atrial fibrillationCardiac disorders | 1/1501 | 5/1508 |
| HaemorrhageVascular disorders | 4/1501 | 3/1508 |
| Wound infectionInfections and infestations | 2/1501 | 4/1508 |
| Postoperative wound infectionInfections and infestations | 3/1501 | 1/1508 |
| Oedema peripheralGeneral disorders | 2/1501 | 2/1508 |
| Wound haemorrhageVascular disorders | 2/1501 | 0/1508 |
| AnaemiaBlood and lymphatic system disorders | 2/1501 | 1/1508 |
| ErysipelasInfections and infestations | 2/1501 | 1/1508 |
| Event | Apixiban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Deep vein thrombosisVascular disorders | 92/1501 | 130/1508 |
| NauseaGastrointestinal disorders | 102/1501 | 120/1508 |
| VomitingGastrointestinal disorders | 77/1501 | 88/1508 |
| ConstipationGastrointestinal disorders | 73/1501 | 77/1508 |
All participants randomized to treatment
| Age, Continuous(Years) | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo | Total |
|---|---|---|---|
| Median | 67 ± 9.85 | 67 ± 9.82 | 67 ± 9.84 |
| Age, Customized(Participants) | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo | Total |
|---|---|---|---|
| Younger than 65 years | 632 | 636 | 1268 |
| 65 years to younger than 75 years | 608 | 576 | 1184 |
| 75 years and older | 288 | 317 | 605 |
| Sex: Female, Male(Participants) | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo | Total |
|---|---|---|---|
| Female | 1089 | 1127 | 2216 |
| Male | 439 | 402 | 841 |
| Race/Ethnicity, Customized(Participants) | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo | Total |
|---|---|---|---|
| White | 1216 | 1211 | 2427 |
| Black/African American | 14 | 17 | 31 |
| Asian | 252 | 254 | 506 |
| Native Hawaiian/Other Pacific Islander | 1 | 1 | 2 |
| Other [Not specified] | 45 | 46 | 91 |
| Hispanic/Latino | 0 | 1 | 1 |
| Not Hispanic/Latino | 53 | 57 | 110 |
| Ethnicity not reported | 1475 | 1471 | 2946 |
| Region of Enrollment(Participants) | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo | Total |
|---|---|---|---|
| Philippines | 12 | 14 | 26 |
| Spain | 61 | 60 | 121 |
| Ukraine | 181 | 182 | 363 |
| Russian Federation | 150 | 156 | 306 |
| Israel | 43 | 43 | 86 |
| Chile | 1 | 5 | 6 |
| Colombia | 36 | 35 | 71 |
| Italy | 69 | 69 | 138 |
| India | 92 | 92 | 184 |
| France | 72 | 68 | 140 |
| Malaysia | 4 | 4 | 8 |
| Denmark | 26 | 23 | 49 |
| South Africa | 56 | 56 | 112 |
| China | 90 | 90 | 180 |
| Korea, Republic of | 40 | 38 | 78 |
| Austria | 156 | 151 | 307 |
| United Kingdom | 63 | 61 | 124 |
| Czech Republic | 48 | 50 | 98 |
| Hungary | 17 | 19 | 36 |
| Mexico | 60 | 59 | 119 |
| Belgium | 27 | 25 | 52 |
| Brazil | 17 | 17 | 34 |
| Poland | 41 | 45 | 86 |
| Singapore | 8 | 9 | 17 |
| Norway | 35 | 36 | 71 |
| Germany | 122 | 122 | 244 |
| Sweden | 1 | 0 | 1 |
| Type of Risk Factor(Participants) | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo | Total |
|---|---|---|---|
| Knee replacement | 257 | 286 | 543 |
| Hip replacement | 90 | 80 | 170 |
| Hip or knee fracture surgery | 55 | 49 | 104 |
| Deep vein thrombosis | 36 | 32 | 68 |
| Pulmonary embolism | 10 | 10 | 20 |
Showing the first 100 of 122 sites across 27 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban